TY - JOUR
T1 - Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma
AU - Arcaini, Luca
AU - Morello, Lucia
AU - Tucci, Alessandra
AU - Rusconi, Chiara
AU - Ladetto, Marco
AU - Rattotti, Sara
AU - Bonfichi, Maurizio
AU - Bottelli, Chiara
AU - Gabutti, Cristina
AU - Bernasconi, Paolo
AU - Varettoni, Marzia
AU - Gotti, Manuel
AU - Troletti, Daniela
AU - Guerrera, Maria Luisa
AU - Fiaccadori, Valeria
AU - Sciarra, Roberta
AU - Ferretti, Virginia Valeria
AU - Alessandrino, Emilio Paolo
AU - Rossi, Giuseppe
AU - Morra, Enrica
N1 - Publisher Copyright:
© 2014 Wiley Periodicals, Inc.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown effective in the control of relapsed/refractory follicular lymphoma. We evaluate the long-term outcome of patients with relapsed or refractory follicular lymphoma treated with ASCT with in vivo purged progenitors cells. We report the long-term results of a prospective multicenter phase 2 trial on 124 relapsed/refractory follicular lymphoma patients treated with a program of anthracycline-based debulking chemotherapy, immunochemotherapy, mobilization of in vivo purged PBSC followed by ASCT. Median age was 52 years; 14% of patients had grade 3A histology. Debulking chemotherapy produced CR in 16% and PR in 71%, while 13% of patients progressed. After rituximab, cyclophosphamide, vincristine, prednisone (R-COP), CR was obtained in 60% and PR in 35%; 118 patients successfully mobilized PBSC and 117 proceeded to ASCT. The harvest in all the 32 molecularly informative patients was bcl-2 negative. TRM was 0%. The 5-year PFS was 54% and the 5-year OS was 83%. After a median f-up of 6.7 years (range 1.5-13.6), 54% are still in CR. These data show that prolonged PFS is achievable in relapsed/refractory patients with high dose autologous transplantation of in vivo purged progenitor cells.
AB - High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown effective in the control of relapsed/refractory follicular lymphoma. We evaluate the long-term outcome of patients with relapsed or refractory follicular lymphoma treated with ASCT with in vivo purged progenitors cells. We report the long-term results of a prospective multicenter phase 2 trial on 124 relapsed/refractory follicular lymphoma patients treated with a program of anthracycline-based debulking chemotherapy, immunochemotherapy, mobilization of in vivo purged PBSC followed by ASCT. Median age was 52 years; 14% of patients had grade 3A histology. Debulking chemotherapy produced CR in 16% and PR in 71%, while 13% of patients progressed. After rituximab, cyclophosphamide, vincristine, prednisone (R-COP), CR was obtained in 60% and PR in 35%; 118 patients successfully mobilized PBSC and 117 proceeded to ASCT. The harvest in all the 32 molecularly informative patients was bcl-2 negative. TRM was 0%. The 5-year PFS was 54% and the 5-year OS was 83%. After a median f-up of 6.7 years (range 1.5-13.6), 54% are still in CR. These data show that prolonged PFS is achievable in relapsed/refractory patients with high dose autologous transplantation of in vivo purged progenitor cells.
UR - http://www.scopus.com/inward/record.url?scp=84923026608&partnerID=8YFLogxK
U2 - 10.1002/ajh.23919
DO - 10.1002/ajh.23919
M3 - Article
SN - 0361-8609
VL - 90
SP - 230
EP - 234
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 3
ER -